ImmunityBio reported completion of a Phase 1 dose-escalation trial (QUILT-3.076; NCT04898543) evaluating autologous memory cytokine-enhanced NK (M-ceNK) cells plus ANKTIVA (nogapendekin alfa inbakicept-pmln) in relapsed or refractory solid tumors. In the treated cohort, 10 patients received weekly intravenous M-ceNK infusions of 0.25–0.75×10^9 cells per dose, for up to 10 doses, with subcutaneous ANKTIVA administered every two weeks. The company reported safety outcomes of 0% grade 4–5 treatment-related adverse events and 0% cytokine storm. ImmunityBio also reported manufacturing engineering programs (NK2022 and NK2023) in 64 subjects, stating that a single apheresis could yield up to 5×10^9 M-ceNK cells and that finished doses could be available within 12 days. Separately, preclinical and in vivo efficacy data for M-ceNK plus ANKTIVA in small cell lung cancer xenograft models were reported as presented by the National Cancer Institute at the AACR IO Annual Meeting in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603130730BIZWIRE_USPR_____20260313_BW323759) on March 13, 2026, and is solely responsible for the information contained therein.
Comments